To include your compound in the COVID-19 Resource Center, submit it here.

Merck gains full rights to IV vernakalant

Astellas Pharma Inc. (Tokyo:4503) transferred North American rights for IV vernakalant to Merck & Co. Inc.

Read the full 166 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE